# Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer

> **NCT03977220** · PHASE1 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Nab-paclitaxel combined with S-1

## Key facts

- **NCT ID:** NCT03977220
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03977220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03977220, "Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03977220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*